• 1. Enantiomorphic symmetry breaking in crystallization of molten sodium chlorate?
  Martin R. Ward,Gary W. Copeland,Andrew J. Alexander Chem. Commun., 2010,46, 7634-7636
• 2. Exceptionally high temperature spin crossover in amide-functionalised 2,6-bis(pyrazol-1-yl)pyridine iron(ii) complex revealed by variable temperature Raman spectroscopy and single crystal X-ray diffraction?
  Max Attwood,Hiroki Akutsu,Lee Martin,Toby J. Blundell,Pierre Le Maguere,Scott S. Turner Dalton Trans., 2021,50, 11843-11851
• 3. Excited state dynamics of symmetric and asymmetric Cr3(dpa)4Cl2 measured using femtosecond transient absorption spectroscopy?
  Chao-Han Cheng,Wen-Zhen Wang,Shie-Ming Peng,I-Chia Chen Phys. Chem. Chem. Phys., 2017,19, 25471-25477
• 4. Emerging investigator series: kinetics of diopside reactivity for carbon mineralization in mafic–ultramafic rocks
  BrianaAguila,LandonHardee,H.ToddSchaef,SiavashZare,MohammadJavadAbdolhosseiniQomi,JarrodV.Crum,JadeE.HollimanJr.,ElenaTajueloRodriguez,LawrenceM.Anovitz,KevinM.Rosso,QuinR.S.Miller
• 5. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Hydroxypyrimidines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Pyrimidines and pyrimidine derivatives Hydroxypyrimidines

Comprehensive Overview of 6-((1r,3r,5r,7r)-Adamantan-2-yl)pyrimidin-4-ol (CAS No. 2098013-25-1)

6-((1r,3r,5r,7r)-Adamantan-2-yl)pyrimidin-4-ol (CAS No. 2098013-25-1) is a structurally unique compound that combines the rigid adamantane framework with a pyrimidin-4-ol moiety. This hybrid structure has garnered significant attention in pharmaceutical and materials science research due to its potential applications in drug discovery and advanced materials. The adamantane group is known for its high stability and lipophilicity, which can enhance the bioavailability of drug candidates, while the pyrimidin-4-ol moiety offers versatile hydrogen-bonding capabilities, making it a valuable scaffold in medicinal chemistry.

The compound's CAS number 2098013-25-1 serves as a unique identifier, ensuring precise communication among researchers and regulatory bodies. In recent years, the demand for adamantane derivatives has surged, driven by their role in developing novel therapeutics for viral infections, neurodegenerative diseases, and cancer. The integration of pyrimidin-4-ol into such frameworks aligns with current trends in fragment-based drug design, where small, well-defined molecular fragments are used to build potent inhibitors.

One of the most intriguing aspects of 6-((1r,3r,5r,7r)-Adamantan-2-yl)pyrimidin-4-ol is its potential as a kinase inhibitor. Kinases are enzymes that play critical roles in cell signaling, and their dysregulation is implicated in numerous diseases. Researchers are particularly interested in how the adamantane group's three-dimensional structure might influence binding affinity and selectivity. This compound's unique geometry could offer advantages over flat, aromatic systems commonly used in kinase inhibitors, potentially reducing off-target effects.

From a synthetic chemistry perspective, the preparation of 6-((1r,3r,5r,7r)-Adamantan-2-yl)pyrimidin-4-ol presents interesting challenges. The adamantane skeleton's steric bulk requires careful optimization of reaction conditions to ensure efficient coupling with the pyrimidine ring. Recent advances in C-H activation and cross-coupling methodologies have opened new routes to such hybrid structures, reducing the need for pre-functionalized starting materials. These innovations align with the pharmaceutical industry's growing emphasis on sustainable and atom-economical synthetic strategies.

In materials science, adamantane-containing compounds have shown promise in creating novel polymers and supramolecular assemblies. The incorporation of 6-((1r,3r,5r,7r)-Adamantan-2-yl)pyrimidin-4-ol into polymer backbones could impart unique thermal and mechanical properties, while the pyrimidin-4-ol group might facilitate hydrogen-bonded network formation. Such materials could find applications in drug delivery systems, where controlled release and biodegradability are crucial considerations.

The compound's physicochemical properties are also noteworthy. The adamantane moiety contributes to high thermal stability and hydrophobicity, while the pyrimidin-4-ol group introduces polarity and hydrogen-bonding capacity. This balanced combination of properties makes 6-((1r,3r,5r,7r)-Adamantan-2-yl)pyrimidin-4-ol particularly interesting for formulation scientists working on solubility enhancement strategies for poorly water-soluble drugs. The current focus on bioavailability improvement in drug development makes this aspect especially relevant.

Recent patent literature reveals growing interest in adamantane-pyrimidine hybrids, with several applications claiming their use as intermediates for antiviral and anticancer agents. The COVID-19 pandemic has accelerated research into broad-spectrum antiviral compounds, and some adamantane derivatives have shown activity against various viral targets. While 6-((1r,3r,5r,7r)-Adamantan-2-yl)pyrimidin-4-ol itself may not be a drug candidate, its structural features make it a valuable building block for medicinal chemistry programs targeting emerging viral threats.

From a commercial perspective, the market for specialized pharmaceutical intermediates like 6-((1r,3r,5r,7r)-Adamantan-2-yl)pyrimidin-4-ol is expanding rapidly. Contract research organizations and custom synthesis providers are increasingly offering such compounds to support drug discovery efforts. The compound's CAS number 2098013-25-1 serves as a crucial identifier in procurement and regulatory documentation, ensuring accurate specification across the supply chain.

Quality control and analytical characterization of 6-((1r,3r,5r,7r)-Adamantan-2-yl)pyrimidin-4-ol typically involve advanced techniques such as HPLC, NMR spectroscopy, and mass spectrometry. The compound's stereochemistry, particularly the configuration of the adamantane substituents, requires careful verification to ensure consistency in biological testing. These analytical considerations are particularly important given the pharmaceutical industry's increasing focus on chiral purity and its impact on drug efficacy and safety.

Looking ahead, the future applications of 6-((1r,3r,5r,7r)-Adamantan-2-yl)pyrimidin-4-ol may extend beyond traditional pharmaceutical uses. The compound's unique structural features could make it valuable in chemical biology as a probe for studying protein-ligand interactions, or in materials science for developing stimuli-responsive systems. As research into adamantane-based materials continues to evolve, this compound may find new roles in emerging technologies such as molecular electronics or advanced coatings.

In summary, 6-((1r,3r,5r,7r)-Adamantan-2-yl)pyrimidin-4-ol (CAS No. 2098013-25-1) represents a fascinating intersection of structural complexity and functional versatility. Its potential applications span drug discovery, materials science, and beyond, making it a compound of significant interest to researchers across multiple disciplines. As synthetic methodologies advance and our understanding of structure-activity relationships deepens, this adamantane-pyrimidine hybrid is likely to play an increasingly important role in the development of novel therapeutic agents and functional materials.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)